Onartuzumab is an investigational drug designed to inhibit cancer growth by blocking a protein on liver cancer cells called the MET antigen. It has been shown in laboratory studies to prevent or slow the growth of human cancer cells. It is given intravenously (by vein)
Sorafenib is a drug used to treat hepatocellular carcinoma (liver cancer). It works by inhibiting the development of the blood vessels that cancer cells need to grow and spread. It is a pill that is taken orally (by mouth). Despite sorafenib treatment, however, many patients with metastatic liver cancer experience continued tumor growth.
In this study, researchers are trying to find the highest dose of onartuzumab that can be given safely with or without sorafenib in patients with advanced liver cancer that has spread or has not responded to other treatment. It is hoped that the combination of these two drugs will be more effective than giving them alone.